{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:51:37Z","timestamp":1768974697962,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":1274,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["CRS13BUT"],"award-info":[{"award-number":["CRS13BUT"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","award":["CF\/20111319"],"award-info":[{"award-number":["CF\/20111319"]}],"id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1074\/jbc.m116.747766","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T01:45:20Z","timestamp":1483062320000},"page":"3552-3567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab"],"prefix":"10.1016","volume":"292","author":[{"given":"Clare T.","family":"Butler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Tosetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene T.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Guiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Cagney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacintha","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breand\u00e1n N.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M116.747766_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcmd.2007.04.001","article-title":"Understanding the biology of angiogenesis: review of the most important molecular mechanisms","volume":"39","author":"Otrock","year":"2007","journal-title":"Blood Cells Mol. Dis"},{"key":"10.1074\/jbc.M116.747766_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in health and disease","volume":"9","author":"Carmeliet","year":"2003","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.M116.747766_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1074\/jbc.M116.747766_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jso.24333","article-title":"The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer","volume":"114","author":"Riaz","year":"2016","journal-title":"J. Surg. Oncol"},{"key":"10.1074\/jbc.M116.747766_bib5","unstructured":"World Health Organization (2012) GLOBOCAN 2012\u2014Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, International Agency for Research on Cancer, Lyon, France"},{"key":"10.1074\/jbc.M116.747766_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1074\/jbc.M116.747766_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.M116.747766_bib8","doi-asserted-by":"crossref","first-page":"C947","DOI":"10.1152\/ajpcell.00389.2001","article-title":"Mechanisms of normal and tumor-derived angiogenesis","volume":"282","author":"Papetti","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1074\/jbc.M116.747766_bib9","doi-asserted-by":"crossref","first-page":"C343","DOI":"10.1152\/ajpcell.00048.2003","article-title":"VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration","volume":"285","author":"van Wetering","year":"2003","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1074\/jbc.M116.747766_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.RES.0000210579.35304.d3","article-title":"Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells","volume":"98","author":"Cernuda-Moroll\u00f3n","year":"2006","journal-title":"Circ. Res"},{"key":"10.1074\/jbc.M116.747766_bib11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10753-011-9409-2","article-title":"The role of Rho\/Rho-kinase pathway in the expression of ICAM-1 by linoleic acid in human aortic endothelial cells","volume":"35","author":"Jung","year":"2012","journal-title":"Inflammation"},{"key":"10.1074\/jbc.M116.747766_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jnci\/djp177","article-title":"How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question","volume":"101","author":"Fojo","year":"2009","journal-title":"J. Natl. Cancer Inst"},{"key":"10.1074\/jbc.M116.747766_bib13","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsb1013826","article-title":"Bending the cost curve in cancer care","volume":"364","author":"Smith","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M116.747766_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","article-title":"Limits on medicare's ability to control rising spending on cancer drugs","volume":"360","author":"Bach","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M116.747766_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-011-0202-z","article-title":"Bevacizumab in the treatment of metastatic breast cancer: friend or foe?","volume":"14","author":"Montero","year":"2012","journal-title":"Curr. Oncol. Rep"},{"key":"10.1074\/jbc.M116.747766_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease","volume":"54","author":"Gunther","year":"2009","journal-title":"Surv. Ophthalmol"},{"key":"10.1074\/jbc.M116.747766_bib17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M116.747766_bib18","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/JTO.0000000000000257","article-title":"Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study","volume":"9","author":"Lynch","year":"2014","journal-title":"J. Thorac. Oncol"},{"key":"10.1074\/jbc.M116.747766_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1947601909356574","article-title":"Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates","volume":"1","author":"Loges","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1074\/jbc.M116.747766_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ctrv.2014.05.006","article-title":"A systematic review of bevacizumab efficacy in breast cancer","volume":"40","author":"K\u00fcmler","year":"2014","journal-title":"Cancer Treat. Rev"},{"key":"10.1074\/jbc.M116.747766_bib21","doi-asserted-by":"crossref","unstructured":"Kotz, J., (2012) Phenotypic screening, take two. Science-Business eXchange 10.1038\/scibx.2012.380","DOI":"10.1038\/scibx.2012.380"},{"key":"10.1074\/jbc.M116.747766_bib22","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1074\/jbc.M115.710665","article-title":"Phenotype-based discovery of 2-[(E)-2-(quinolin-2-yl)vinyl]phenol as a novel regulator of ocular angiogenesis","volume":"291","author":"Reynolds","year":"2016","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M116.747766_bib23","doi-asserted-by":"crossref","first-page":"34523","DOI":"10.1038\/srep34523","article-title":"Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer","volume":"6","author":"Murphy","year":"2016","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.M116.747766_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2016.04.004","article-title":"A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo","volume":"233","author":"Galvin","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1074\/jbc.M116.747766_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prostaglandins.2015.12.001","article-title":"Role of leukotrienes in diabetic retinopathy","volume":"122","author":"Behl","year":"2016","journal-title":"Prostaglandins Other Lipid Mediators"},{"key":"10.1074\/jbc.M116.747766_bib26","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M116.747766_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ejca.2009.12.022","article-title":"Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer","volume":"46","author":"Magnusson","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1074\/jbc.M116.747766_bib28","doi-asserted-by":"crossref","first-page":"E413","DOI":"10.25011\/cim.v33i6.14593","article-title":"Effects of montelukast on burn wound healing in a rat model","volume":"33","author":"Turtay","year":"2010","journal-title":"Clin. Invest. Med"},{"key":"10.1074\/jbc.M116.747766_bib29","unstructured":"Kennedy, B. N., Reynolds, A., Kilty, C., O'Sullivan, J., and Baxter, A. D., (January 23, 2014) Anti-angiogenic Compounds. Patent WO 2014012889 A1"},{"key":"10.1074\/jbc.M116.747766_bib30","doi-asserted-by":"crossref","first-page":"11386","DOI":"10.1158\/0008-5472.CAN-07-3126","article-title":"Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish","volume":"67","author":"Tran","year":"2007","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.M116.747766_bib31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M116.747766_bib32","first-page":"304","article-title":"Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences","volume":"2","author":"Edelman","year":"2013","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1074\/jbc.M116.747766_bib33","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.semcancer.2015.01.001","article-title":"Broad targeting of angiogenesis for cancer prevention and therapy","volume":"35","author":"Wang","year":"2015","journal-title":"Semin. Cancer Biol"},{"key":"10.1074\/jbc.M116.747766_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1026598300052","article-title":"Zebrafish angiogenesis: a new model for drug screening","volume":"3","author":"Serbedzija","year":"1999","journal-title":"Angiogenesis"},{"key":"10.1074\/jbc.M116.747766_bib35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3748\/wjg.v20.i4.968","article-title":"Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer","volume":"20","author":"Savari","year":"2014","journal-title":"World J. Gastroenterol"},{"key":"10.1074\/jbc.M116.747766_bib36","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1021\/jm00099a011","volume":"35","author":"Zamboni","year":"1992","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M116.747766_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0026-895X(25)11001-8","article-title":"Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity","volume":"39","author":"Murphy","year":"1991","journal-title":"Mol. Pharmacol"},{"key":"10.1074\/jbc.M116.747766_bib38","first-page":"750","article-title":"Involvement of cysteinyl leukotriene receptors in angiogenesis in rat thoracic aortic rings","volume":"65","author":"Xu","year":"2010","journal-title":"Pharmazie"},{"key":"10.1074\/jbc.M116.747766_bib39","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/srep03274","article-title":"Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors","volume":"3","author":"Duah","year":"2013","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.M116.747766_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/gast.2003.50011","article-title":"Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas","volume":"124","author":"Ohd","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1074\/jbc.M116.747766_bib41","doi-asserted-by":"crossref","first-page":"23979","DOI":"10.1038\/srep23979","article-title":"Cysteinyl leukotriene receptor antagonists decrease cancer risk in asthma patients","volume":"6","author":"Tsai","year":"2016","journal-title":"Sci. Rep"},{"key":"10.1074\/jbc.M116.747766_bib42","series-title":"In vitro assays","article-title":"Chapter 2, Angiogenesis Assays, in Angiogenesis Section 2.1","author":"Adair","year":"2010"},{"key":"10.1074\/jbc.M116.747766_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1074\/jbc.M116.747766_bib44","first-page":"346","article-title":"Angiogenesis by capillary endothelial cells in culture","volume":"100","author":"Folkman","year":"1980","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"10.1074\/jbc.M116.747766_bib45","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nprot.2010.6","article-title":"In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract","volume":"5","author":"Arnaoutova","year":"2010","journal-title":"Nat. Protoc"},{"key":"10.1074\/jbc.M116.747766_bib46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":"Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol"},{"key":"10.1074\/jbc.M116.747766_bib47","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1158\/0008-5472.CAN-06-3494","article-title":"Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A","volume":"67","author":"Jia","year":"2007","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.M116.747766_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fcell.2016.00103","article-title":"Evaluation of cysteinyl leukotriene signaling as a therapeutic target for colorectal cancer","volume":"4","author":"Burke","year":"2016","journal-title":"Front. Cell Dev. Biol"},{"key":"10.1074\/jbc.M116.747766_bib49","doi-asserted-by":"crossref","first-page":"29555","DOI":"10.1074\/jbc.M115.678292","article-title":"Ca2+ influx through store-operated calcium channels replenishes the functional phosphatidylinositol 4,5-bisphosphate pool used by cysteinyl leukotriene type I receptors","volume":"290","author":"Alswied","year":"2015","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M116.747766_bib50","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1096\/fj.05-5354com","article-title":"Calpain-2 regulation of VEGF-mediated angiogenesis","volume":"20","author":"Su","year":"2006","journal-title":"FASEB J"},{"key":"10.1074\/jbc.M116.747766_bib51","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1023\/B:NERE.0000026410.56000.dd","article-title":"The effects of calpain inhibition on I\u03baB\u03b1 degradation after activation of PBMCs: identification of the calpain cleavage sites","volume":"29","author":"Schaecher","year":"2004","journal-title":"Neurochem. Res"},{"key":"10.1074\/jbc.M116.747766_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00432-012-1366-0","article-title":"Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-\u03baB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities","volume":"139","author":"Spirina","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"10.1074\/jbc.M116.747766_bib53","unstructured":"Lin, T. J., (May 19, 2011) Inhibition of Calpain Reduces Allergic Inflammation. U. S. Patent 20110117106 A1"},{"key":"10.1074\/jbc.M116.747766_bib54","first-page":"725","article-title":"Constitutive NF-\u03baB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma","volume":"23","author":"Xie","year":"2010","journal-title":"Oncol. Rep"},{"key":"10.1074\/jbc.M116.747766_bib55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/092986707779941113","article-title":"NF-\u03baB inhibitors for the treatment of inflammatory diseases and cancer","volume":"14","author":"Calzado","year":"2007","journal-title":"Curr. Med. Chem"},{"key":"10.1074\/jbc.M116.747766_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrd2781","article-title":"Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls","volume":"8","author":"Baud","year":"2009","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1074\/jbc.M116.747766_bib57","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3390\/cells5020015","article-title":"Roles of NF-\u03baB in cancer and inflammatory diseases and their therapeutic approaches","volume":"5","author":"Park","year":"2016","journal-title":"Cells"},{"key":"10.1074\/jbc.M116.747766_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.RES.0000235986.35957.a3","article-title":"Essential role of ICAM-1\/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium","volume":"99","author":"Wu","year":"2006","journal-title":"Circ. Res"},{"key":"10.1074\/jbc.M116.747766_bib59","series-title":"Angiogenesis in Health, Disease and Malignancy","first-page":"375","author":"Salajegheh","year":"2016"},{"key":"10.1074\/jbc.M116.747766_bib60","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1074\/jbc.M116.747766_bib61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.cr.7290176","article-title":"The enigmatic role of angiopoietin-1 in tumor angiogenesis","volume":"13","author":"Metheny-Barlow","year":"2003","journal-title":"Cell Res"},{"key":"10.1074\/jbc.M116.747766_bib62","doi-asserted-by":"crossref","first-page":"e77117","DOI":"10.1371\/journal.pone.0077117","article-title":"The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer","volume":"8","author":"Lieu","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820348687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820348687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M116.747766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:24:10Z","timestamp":1749857050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820348687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0021925820348687"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m116.747766","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.M116.747766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}